A5064016033- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Circular RNAs in diseases
- HER2/EGFR in Cancer Research
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Palliative Care and End-of-Life Issues
- Viral-associated cancers and disorders
- Cancer Research and Treatments
Ramathibodi Hospital
2016-2025
Mahidol University
2016-2025
Roswell Park Comprehensive Cancer Center
2010-2014
University at Buffalo, State University of New York
2011
Hospice Buffalo
2011
Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head neck squamous cell carcinoma KEYNOTE-048. Post hoc analysis of long-term progression-free survival on next-line therapy (PFS2) is presented.
The phase III KEYNOTE-048 (ClinicalTrials.gov identifier: NCT02358031) trial of pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) included planned efficacy analyses the total population participants with programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥ 1 CPS 20. To further characterize predictive value PD-L1 expression on outcome, we conducted < 1-19 subgroups KEYNOTE-048.
6000 Background: KEYNOTE-048 is a phase 3 study of P or + chemo (C) vs EXTREME (E) as 1L therapy for R/M HNSCC (NCT02358031). At the second interim analysis (IA2), significantly improved OS in PD-L1 combined positive score (CPS) ≥20 and ≥1 populations had noninferior total population with favorable safety; P+C comparable safety. We present protocol-specified final results. Methods: 882 pts locally incurable no prior systemic setting who provided tumor sample testing were randomized to 200 mg...
•No difference was observed in efficacy between pembrolizumab and chemotherapy advanced platinum-pretreated NPC. •Median OS 17.2 months with versus 15.3 (median PFS, 4.1 5.5 months. •Pembrolizumab had manageable safety a lower incidence of treatment-related adverse events (AEs) than chemotherapy. •Grade 3-5 AEs occurred 10.3% participants treated 43.8% Background Pembrolizumab previously demonstrated robust antitumor activity phase Ib study patients heavily pretreated, programmed death...
PURPOSE The incidence and survival rates of head neck squamous cell carcinoma (HNSCC) nasopharyngeal (NPC) vary globally, influenced by factors such as ethnicity, lifestyle, health care systems. METHODS A retrospective analysis was conducted on patients with HNSCC treated between 2008 2020 in four major Thai academic cancer centers, using a multidisciplinary multicenter database. study focused the evolution patient characteristics, changes, treatment landscape alterations over time. RESULTS...
Objectives: Immunotherapies that target the programmed death-1/ death-1 ligand (PD-1/PD-L1) immune checkpoint pathway have shown promise in nasopharyngeal carcinoma (NPC) early phases clinical studies. Here, we evaluated PD-1 and PD-L1 expression CD8+ tumor-infiltrating lymphocytes (TILs) NPC patients. Materials Methods: Newly diagnosed patients were identified through institutional database between January 2007 December 2012. expression, Epstein-Barr virus (EBV) status, TIL numbers measured...
The benefit of postoperative chemoradiotherapy (CRT) over radiotherapy (RT) alone remains unclear for resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) patients with intermediate risk(s) such as pT3 or pT4 primary, pN2 pN3 nodal disease, disease in levels IV V, perineural invasion (PNI), lymphovascular (LVI). This study aims to evaluate the benefits CRT multiple risks. LA-HNSCC who underwent curative surgery risk at our institution were identified. A propensity...
To assess health-related quality of life (HRQoL) with first-line pembrolizumab, pembrolizumab-chemotherapy, or cetuximab-chemotherapy in recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) the phase 3 KEYNOTE-048 trial (NCT02358031).
Lower prevalence HPV infection has been previously reported in Thai population when compared with Western countries. p16 expression indicates HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but not non-OPSCC. We therefore evaluated the characteristic and association of patients HNSCC.We used immunohistochemistry qPCR, respectively, to detect DNA archrival formalin-fixed paraffin-embedded HNSCC tissues. Patient characteristics survival were analyzed.p16 was detected tumors 72...
Abstract Background R/M‐HNSCC patients typically receive 1L platinum‐based chemotherapy with pembrolizumab or cetuximab. However, the outcomes for early recurrence (<6 months) remain unclear due to their exclusion from most studies. This study aimed assess impact of time‐to‐recurrence intervals (TTRI) and patterns on survival patients. Methods We identified non‐curable at our institution 1/2008 through 6/2020. analyzed recurrent who received systemic treatment, different TTRIs patterns....
Metastatic breast cancer patients have many options for therapy and may be at risk late or absent hospice referrals, which make meaningful improvements in symptoms quality of life difficult to achieve.We aimed examine utilization, status on admission, care treated metastatic from 1999 2010 a National Cancer Institute (NCI)-designated comprehensive center located Western New York.We conducted retrospective database review that identified 182 with deaths resulting who were eligible services...
6505 Background: 1L P vs E improved OS in PD-L1 CPS ≥20 and ≥1 populations, led to noninferior the total population, with favorable safety; P+C had superior ≥20, ≥1, populations comparable safety phase 3 KEYNOTE-048 study (NCT02358031) patients R/M HNSCC. Neither nor PFS or populations. Here, we present progression after next line of therapy (PFS2) assess effect subsequent anticancer on patient outcomes. Methods: Patients locally incurable HNSCC no prior systemic setting were randomly...
Abstract Poor survival of patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) is partly due to early diagnosis difficulties the lack reliable biomarkers for predicting treatment outcomes. In discovery cohort, plasma‐derived extracellular vesicles (EVs) from LA‐HNSCC (n = 48) healthy volunteers 12) were used profiling microRNA (miRNA) expression by NanoString analysis. Ten EV‐associated miRNAs differentially expressed between volunteers. Subsequently, results...
PURPOSE Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CRT-AC) and induction concurrent (IC-CRT) are among the best treatments in nasopharyngeal carcinoma (NPC). This study aimed to develop a model for deciding sequence of NPC. METHODS Data were separated into two cohorts. The CRT-AC cohort had 295 patients, while IC-CRT 112. predictors standard factors with BMI neutrophil-lymphocyte ratio (NLR) predict overall survival (OS). A flexible parametric was used. RESULTS total 132...